Table 4.
Risk of Neurologic Disorders Developing During Follow-Up Among Patients With and Without Generalized BP
| Neurologic Disorder | Patients Without BPa |
Patients With BPa |
HR (95% CI)b |
P Value |
|---|---|---|---|---|
| Dementia | 28/189 (15) | 9/64 (14) | 1.29 (0.60–2.75) | .51 |
| Parkinson disease | 2/213 (1) | 4/71 (6) | 8.44 (1.53–46.56) | .01 |
| MS | 1/215 (<1) | 0/72 (0) | NA | .64c |
| Cerebrovascular disease | 9/205 (4) | 4/70 (6) | 1.78 (0.54–5.81) | .34 |
| Seizures | 1/210 (<1) | 1/70 (1) | 5.30 (0.33–84.84) | .24 |
| Any of the above | 35/161 (22) | 16/56 (29) | 1.89 (1.04–3.42) | .04 |
| Dementia or Parkinson disease | 30/183 (16) | 13/62 (21) | 1.76 (0.91–3.39) | .09 |
| Dementia, Parkinson disease, or MS | 31/179 (17) | 13/61 (21) | 1.69 (0.88–3.25) | .12 |
| Dementia, Parkinson disease, MS, or cerebrovascular disease | 37/170 (22) | 16/59 (27) | 1.78 (0.99–3.21) | .05 |
Abbreviations: BP, bullous pemphigoid; HR, hazard ratio; MS, multiple sclerosis; NA, not applicable.
a
Values are No. of patients/No. of patients assessed (%).
b
Risk of neurologic disorder developing during follow-up for patients with generalized BP compared with patients without BP.
c
Log-rank test.